Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024.

Alnylam Pharmaceuticals presented new data from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), at the Heart Failure Society of America Annual Scientific Meeting. The data showed that vutrisiran slowed disease progression in patients with ATTR-CM, as evidenced by improvements in cardiac structure and function. These findings suggest that vutrisiran may have a disease-modifying effect and could potentially become a first-line therapy for ATTR amyloidosis with cardiomyopathy. Alnylam is on track to complete multiple global regulatory submissions for vutrisiran by the end of the year. [Extracted from the article]